Search Result
Results for "
Food intake
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1215A
-
|
Melanocortin Receptor
|
Metabolic Disease
|
HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
|
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-P1216A
-
|
Melanocortin Receptor
|
Neurological Disease
|
HS014 TFA is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors respectively. HS014 TFA increases food intake in free-feeding rats .
|
-
-
- HY-121827
-
|
Cannabinoid Receptor
|
Metabolic Disease
|
LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats.
, and displays efficacy as a feeding inhibitor .
|
-
-
- HY-P2210
-
|
GPR171
|
Metabolic Disease
|
BigLEN(mouse) is a potent and selective agonist of orphan G protein-coupled receptor 171 (GPR171), with a Kd of ∼0.5 nM. BigLEN(mouse) can be used to regulate responses associated with food intake and metabolism .
|
-
-
- HY-114976
-
-
-
- HY-P1215
-
|
Melanocortin Receptor
|
Metabolic Disease
|
HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
|
-
-
- HY-105034
-
BMY 13859-1 free base
|
5-HT Receptor
|
Neurological Disease
|
Tiospirone is a 5-HT2 receptor antagonist with affinity for D2, 5-HT1a, and 5-HT7, and sigma receptors. Tiospirone decreases consumption of ethanol while increasing food intake of rats. Tiospirone can also reduce the reinforcing properties of Cocaine exhibited in the conditioned place preference paradigm .
|
-
-
- HY-P2046
-
|
Opioid Receptor
|
Neurological Disease
|
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .
|
-
-
- HY-139799
-
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
Sch 202596 is a non-peptide antagonist of the galanin receptor subtype GalR1. Sch 202596 blocks the action of galanin by binding to GalR1, thereby reducing food intake. Sch 202596 can be used in the study of obesity and related eating disorders .
|
-
-
- HY-W010042
-
L-(-)-Glucose
|
Others
|
Metabolic Disease
Cancer
|
L-Glucose (L-(-)-Glucose) is a stereoisomer of D-Glucose (HY-B0389), which does not readily enter the brain. L-Glucose can promote food intake. L-glucose is combined with a fluorescence detector to produce a fluorescent probe that can be used to visualize and characterize cancer cells. L-Glucose also can be used in the research to enhance memory in mice .
|
-
-
- HY-124821
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
VA012 (compound 11) is a positive allosteric modulator (PAM) of the serotonin 5-HT2C receptor. VA012 reduces food intake and body weight gain without causing CNS-related malaise during subchronic administration. VA012 can be utilized in obesity research .
|
-
-
- HY-P3561
-
|
Melanocortin Receptor
|
Neurological Disease
|
Agouti-related Protein (AGRP) (83-132) Amide (human) is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
|
-
-
- HY-118949
-
|
Opioid Receptor
|
Metabolic Disease
|
LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity .
|
-
-
- HY-P3561A
-
|
Melanocortin Receptor
|
Neurological Disease
|
Agouti-related Protein (AGRP) (83-132) Amide (human) TFA is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
|
-
-
- HY-P3130
-
|
CRFR
|
Neurological Disease
Inflammation/Immunology
|
Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .
|
-
-
- HY-P1216
-
|
Melanocortin Receptor
|
Neurological Disease
|
HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats .
|
-
-
- HY-P1322
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
|
-
-
- HY-120096
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
BIBO3304 free base is a nonpeptide neuropeptide Y Y1 receptor antagonist. BIBO3304 free base displays subnanomolar affinity for both the human and the rat Y1 receptor, with IC50 values of 0.38 nM and 0.72 nM, respectively. BIBO3304 free base significantly inhibits food intake induced by application of NPY or by fasting .
|
-
-
- HY-P1322A
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats .
|
-
-
- HY-116797
-
MS0015203
|
GPR171
|
Metabolic Disease
|
MS15203 is a potent and selective GPR171 agonist. MS15203 increases food intake and body weight. MS15203 increases neuronal activity. MS15203 significantly increases the abundance of the mRNAs encoding proSAAS, NPY, AgRP .
|
-
-
- HY-P1306
-
|
GHSR
|
Cardiovascular Disease
Inflammation/Immunology
|
Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
|
-
-
- HY-P1306A
-
|
GHSR
|
Cardiovascular Disease
Inflammation/Immunology
|
Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
|
-
-
- HY-165393
-
N-(9E)-9-Octadecen-1-ylsulfamide
|
PPAR
|
Metabolic Disease
|
Elaidyl-sulfamide (N-(9E)-9-Octadecen-1-ylsulfamide) is a PPARα agonist. Elaidyl-sulfamide reduces body weight gain and food intake and reduces circulating cholesterol levels and increases both glucose and insulin levels. Elaidyl-sulfamide has the potential for the research of complicated obesity .
|
-
-
- HY-19848
-
LBM-642
|
PPAR
|
Metabolic Disease
|
Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
|
-
-
- HY-P1323
-
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
[Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake .
|
-
-
- HY-P1323A
-
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake .
|
-
-
- HY-P3463
-
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-163996
-
|
GLP Receptor
|
Metabolic Disease
|
DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity .
|
-
-
- HY-119203
-
|
Histamine Receptor
|
Metabolic Disease
|
NNC 38-1049 is an orally active, potent and competitive histamine H3 receptor antagonist. NNC 38-1049 produced an increase in extracellular levels of histamine in the paraventricular nucleus. NNC 38-1049 decreases food intake and body weight, which is promising for research of obesity .
|
-
-
- HY-14342
-
MK-5046
2 Publications Verification
|
Bombesin Receptor
|
Metabolic Disease
|
MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
|
-
-
- HY-149663
-
|
Acyltransferase
|
Metabolic Disease
|
BMS-986172 is an orally active, highly selective MGAT2 inhibitor with an IC50 of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 has a T1/2>120 min in vitro assays. BMS-986172 reduces food intake and body weight. BMS-986172 has the potential for metabolic disorders such as obesity and NASH research .
|
-
-
- HY-14495
-
EX-1314
|
GHSR
|
Metabolic Disease
|
BMS-604992 (EX-1314) is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (Ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 can stimulate food intake in rodents .
|
-
-
- HY-14495B
-
EX-1314 dihydrochloride
|
GHSR
|
Metabolic Disease
|
BMS-604992 (EX-1314) dihydrochloride is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 dihydrochloride demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 dihydrochloride can stimulate food intake in rodents .
|
-
-
- HY-101764
-
SR 27897
|
Cholecystokinin Receptor
|
Metabolic Disease
|
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
|
-
-
- HY-14495A
-
EX-1314 free base
|
GHSR
|
Metabolic Disease
|
BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 free base can stimulate food intake in rodents .
|
-
-
- HY-14342A
-
|
Others
|
Metabolic Disease
|
(R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
|
-
-
- HY-117158
-
|
Others
|
Others
|
SKF 89748 is an α1-adrenergic receptor agonist with the activity of inhibiting food and water intake. SKF 89748 inhibits food and water intake in adult male rats with an ED50 of 0.37mg/kg for inhibiting food intake.
|
-
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-135238
-
PD-117302
|
Others
|
Others
|
(rel)-RSD 921 (PD-117302) is a κ agonist that is more sensitive to its initial food-inducing effect in obese and lean Zucker rats, but ultimately reduces food intake. The compound does not enhance food intake more in obese Zucker rats than in lean rats.
|
-
-
- HY-W010042S
-
-
-
- HY-W010042S1
-
-
-
- HY-W010042S2
-
-
-
- HY-W127334
-
|
Biochemical Assay Reagents
|
Others
|
N-Palmitoyl phosphatidylethanolamine (Tripelargonin) is endogenous lipid anorectic hormone, significantly reduces food intake in a dose-dependent manner
|
-
-
- HY-120828
-
CJC 1134PC
|
GLP Receptor
|
Metabolic Disease
|
Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice .
|
-
-
- HY-101480
-
|
Others
|
Neurological Disease
|
Xylamidine is a peripheral 5-HT receptor antagonist used to investigate possible peripheral appetite suppressant effects of 5-hydroxytryptophan (5-HTP) and fenfluramine. In a 1-hour food intake test, xylamidine attenuated the decrease in food intake induced by 5-HT and 5-HTP, but had no effect on fenfluramine, suggesting that the appetite suppressant effect of 5-HTP is mediated in part through peripheral 5-HT receptors. Microstructural analysis revealed that 5-HTP and fenfluramine induced a decrease in food intake rate and a reduction in feeding batch size. Xylamidine reversed the effects of 5-HTP on food intake rate and induced a slight increase in feeding batch size itself, thus, the peripheral effect of 5-HTP appears to be to slow food intake rate. No effect of xylamidine on fenfluramine-induced changes in feeding was observed. The results suggest that the appetite suppressant effects of 5-HTP and fenfluramine are differentiated based on the peripheral effects of 5-HTP. The peripheral effects of 5-HTP are distinct from the previously reported 5-HT-induced decreases in feeding batch size and duration. Possible mechanisms underlying the differences in peripheral effects of 5-HT and 5-HTP are discussed.
|
-
-
- HY-N11948
-
|
Others
|
Others
|
Simmondsin, derived from the jojoba plant (Simmondsia chinensis), has been shown to decrease food intake and body weight in rats without any noticeable adverse effects.
|
-
-
- HY-110107
-
-
- HY-107728
-
-
- HY-110020
-
-
- HY-14811
-
ZGN-440; CKD-732 free base
|
MetAP
|
Metabolic Disease
|
Beloranib is a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor. Beloranib decreases food intake, body weight, fat mass, and the size of adipocytes .
|
-
- HY-129207
-
|
GHSR
|
Endocrinology
|
Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor that stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. JMV3002 is a potent ghrelin receptor antagonist with an IC50 value of 1.1 nM in vitro. 80 μg/kg, JMV3002 inhibits hexarelin-stimulated food intake by as much as 98% in rats. JMV3002 alone does not elicit growth hormone release nor does it inhibit hexarelin-stimulated growth hormone secretion when tested in infant rats at a dose of 160 μg/kg.
|
-
- HY-107627
-
|
Melanocortin Receptor
|
Inflammation/Immunology
|
MCL0020 is a potent and selective melanocortin MC4 receptor antagonist, with an IC50 of 11.63 nM. MCL0020 dose-dependently and significantly attenuates restraint stress-induced anorexia without affecting food intake .
|
-
- HY-W010042S3
-
-
- HY-16007
-
Garcinia acid
|
ATP Citrate Lyase
|
Metabolic Disease
|
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive and orally active inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss .
|
-
- HY-P4815
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .
|
-
- HY-135319
-
|
Others
|
Infection
|
Strictinin is a phenolic compound isolated from Pu'er teas. Strictinin has potential antiviral, antibacterial and laxative activities. Strictinin occurs by accelerating intestinal transit rather than enhancing gastric emptying, increasing food intake, or inducing diarrhea in rats.
|
-
- HY-19656
-
|
Others
|
Metabolic Disease
|
HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research .
|
-
- HY-107734
-
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a Ki of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .
|
-
- HY-P0198B
-
-
- HY-111583
-
|
RXFP Receptor
|
Metabolic Disease
|
RXFP3/4 agonist 1 is an agonist of relaxin family peptide 3/4 receptor (RXFP3/4), with EC50s of 82/2 nM, respectivley. RXFP3/4 agonist 1 increases food intake in rats .
|
-
- HY-124399
-
|
Endogenous Metabolite
PPAR
|
Metabolic Disease
|
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
|
-
- HY-14788
-
AVE1625
|
Cannabinoid Receptor
|
Metabolic Disease
|
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R .
|
-
- HY-103416
-
|
Dopamine Receptor
|
Neurological Disease
|
A-77636 hydrochloride is a potent, orally active, selective and long acting dopamine D1 receptor agonist (pKi=7.40; Ki=39.8 nM) with antiparkinsonian activity. A-77636 hydrochloride is functionally inactive at dopamine D2 receptor .
|
-
- HY-P1096
-
|
Cholecystokinin Receptor
|
Metabolic Disease
|
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
|
-
- HY-103327
-
|
Cannabinoid Receptor
|
Metabolic Disease
|
MJ15 is a potent and selective CB1 receptor antagonist with a Ki of 27.2 pM and an IC50 of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice .
|
-
- HY-P2703
-
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system .
|
-
- HY-153798
-
|
GLP Receptor
|
Metabolic Disease
|
GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity .
|
-
- HY-125088
-
|
Others
|
Others
|
Oleoyl-estrone (OE) is a signaling molecule derived from adipose tissue that reduces energy intake and body fat while maintaining energy expenditure and blood glucose balance. In studies in adrenalodepleted female rats, administration of OE resulted in significant fat mobilization, reduced food intake, and sustained energy expenditure. However, concomitant administration of corticosterone inhibits OE-induced fat mobilization and aggravates insulin resistance and glycemic imbalance by promoting fat deposition. This suggests that corticosterone has an antagonistic effect on the beneficial metabolic effects of OE, particularly on lipid metabolism and insulin sensitivity .
|
-
- HY-107727
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
BMS-193885 (L-Lactic acid) is a potent, selective, and brain-penetrant neuropeptide Y1 receptor antagonist. BMS-193885 has a Ki value of 3.3 nM for the neuropeptide Y1 receptor, competitively acts on the neuropeptide Y binding site, and can reduce food intake and body weight through central Y1 inhibition .
|
-
- HY-P1525
-
MCH (salmon)
|
MCHR1 (GPR24)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
|
-
- HY-14811A
-
ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate
|
MetAP
|
Metabolic Disease
|
Beloranib (ZGN-440; ZGN-433) hemioxalate is a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor. Beloranib hemioxalate decreases food intake, body weight, fat mass, and the size of adipocytes. Beloranib hemioxalate plays an important role in anti-obesity activity or obesity research .
|
-
- HY-117119
-
|
5-HT Receptor
|
Metabolic Disease
|
VER-3323 is an oral active 5-HT2C agonist and belongs to the class of indoline analogs. VER-3323 reduces food intake in rats by inducing swallowing dysfunction, with no significant impact on energy expenditure generated through thermogenesis or exercise. VER-3323 can be utilized in obesity research .
|
-
- HY-16673
-
|
GPR119
|
Metabolic Disease
|
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC50=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders .
|
-
- HY-P1296
-
Urocortin (Rattus norvegicus); Rat urocortin
|
CRFR
|
Neurological Disease
Endocrinology
|
Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively .
|
-
- HY-137061
-
-
- HY-P1525A
-
MCH (salmon) (TFA)
|
MCHR1 (GPR24)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
|
-
- HY-122964
-
|
Cannabinoid Receptor
|
Metabolic Disease
|
URB447 is a peripherally restricted CB1 cannabinoid antagonist (IC50: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB1-dependent responses. URB447 can be used for research of obesity .
|
-
- HY-165495
-
|
Adrenergic Receptor
|
Cardiovascular Disease
|
Pafenolol is a selectively oral-active β1 adrenergic receptor (β1-adrenergic receptor) antagonist that effectively lowers blood pressure. Pharmacokinetic studies in rats indicate that the absorption of Pafenolol is influenced by gastrointestinal contents, with food intake reducing the bioavailability of Pafenolol in rats. Pafenolol can be used in research related to cardiovascular diseases and asthma .
|
-
- HY-153993
-
|
Others
|
Others
|
Pyrocatechol sulfate, a phenolic metabolite present in human plasma, is associated with the consumption of specific foods such as berries and the condition of gut microbiota. It serves as a potential urinary biomarker for kidney function, dialytic clearance, whole grain consumption, and regular coffee intake. Additionally, Pyrocatechol sulfate, along with other phenolic sulfates, plays a role in modulating various biological functions, including those related to brain health and the rhythmic beating of cardiomyocytes.
|
-
- HY-P1317
-
|
Opioid Receptor
|
Neurological Disease
|
Nociceptin (1-13), amide is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
|
-
- HY-P1296A
-
Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA
|
CRFR
|
Neurological Disease
Endocrinology
|
Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively .
|
-
- HY-P1317A
-
|
Opioid Receptor
|
Neurological Disease
|
Nociceptin (1-13), amide TFA is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
|
-
- HY-W011220
-
ADD-3878; U-63287
|
PPAR
|
Cardiovascular Disease
Cancer
|
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .
|
-
- HY-113421
-
Linoleic acid monoethanolamide
|
Cannabinoid Receptor
|
Neurological Disease
|
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1(CB1)and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
|
-
- HY-158014
-
|
Dopamine Transporter
|
Neurological Disease
|
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
|
-
- HY-P1349A
-
Rat orexin B TFA; Orexin B (mouse) (TFA)
|
Orexin Receptor (OX Receptor)
|
Neurological Disease
Endocrinology
|
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation .
|
-
- HY-155967
-
|
AMPK
Cannabinoid Receptor
|
Metabolic Disease
|
CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity .
|
-
- HY-162703
-
|
AMPK
|
Metabolic Disease
|
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
|
-
- HY-P2242A
-
|
Melanocortin Receptor
|
Neurological Disease
Inflammation/Immunology
|
RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects .
|
-
- HY-100546
-
|
Histone Demethylase
|
Infection
Metabolic Disease
Cancer
|
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .
|
-
- HY-P10380
-
|
Neuropeptide FF Receptor
|
Neurological Disease
|
palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
|
-
- HY-P1324
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
|
-
- HY-P1324A
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
|
-
- HY-101365
-
|
5-HT Receptor
|
Neurological Disease
|
RS-102221 is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 can promote the differentiation of new nerve cells. RS-102221 increases food-intake and weight-gain in rats .
|
-
- HY-101365A
-
|
5-HT Receptor
|
Neurological Disease
|
RS-102221 hydrochloride is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 hydrochloride shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 hydrochloride can promote the differentiation of new nerve cells. RS-102221 hydrochloride increases food-intake and weight-gain in rats .
|
-
- HY-12191
-
|
Histamine Receptor
|
Metabolic Disease
|
A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
|
-
- HY-150700
-
|
ERK
|
Metabolic Disease
|
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome .
|
-
- HY-14229
-
CCDC
|
G protein-coupled Bile Acid Receptor 1
Calcium Channel
|
Metabolic Disease
|
TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca 2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .
|
-
- HY-N6711
-
|
HIV Integrase
Bacterial
|
Infection
Metabolic Disease
|
Equisetin is an N-methylserine-derived acyltramic acid isolated from the terrestrial fungus Fusarium equiseti NRRL 5537. As a tetrad-containing natural product, it has antibacterial and antiviral activities, inhibiting the growth of Gram-positive bacteria and HIV-1 integrase activity, but not Gram-negative bacteria. Equisetin is a quorum sensing inhibitor (QSI) that attenuates the QS-regulated virulence phenotype in Pseudomonas aeruginosa without affecting bacterial growth, and is a leading compound for studying Pseudomonas aeruginosa infection. In addition, equisetin inhibits the enzymatic activity of 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) without affecting food intake, blood pressure, or heart rate, exerting anti-obesity effects on adipose tissue .
|
-
- HY-117146
-
(S)-DPX-JW062
|
Others
|
Infection
|
Indoxacarb ((S)-DPX-JW062) is an oxathiazole insecticide with activity against a wide range of insect pests. Indoxacarb is used in forest pest management to control insect pests, and its toxicity has significant effects on adult individuals of the predatory stink bug Podisus distinctus. Indoxacarb showed high toxicity to P. distinctus at a lethal concentration (LC50 = 2.62 g L-1). Indoxacarb treatment significantly reduced the survival rate of P. distinctus, with the survival rate of individuals exposed to 2.62 g L-1 decreasing to 40.7%. Indoxacarb also reduced the respiration rate of P. distinctus from 18.45 to 14.41 μL CO2 h-1, and inhibited its food intake. P. distinctus showed hyperexcitatory responses after Indoxacarb treatment .
|
-
- HY-110206
-
|
Cannabinoid Receptor
|
Metabolic Disease
|
AM6545 is a peripherally active, cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2 receptors with Kis of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications .
|
-
-
-
HY-L094
-
|
2,005 compounds
|
The health benefits deriving from the consumption of certain foods have been common knowledge. All foods are made up of chemical substances. Chemicals in foods are largely harmless and often desirable. At present, numerous researchers have been focused on the beneficial role played by certain food components in the close relationship between food intake and health status. For example, polyphenols, a common class of compounds among foods, are well-known antioxidants, which may play a role in the prevention of several diseases including type 2 diabetes, cardiovascular diseases, and some types of cancer.
MCE supplies a unique collection of 2,005 compounds from variety of foods. All compounds are with specific food source(s). MCE Food-Sourced Compound Library is the useful tool to discover molecules with pharmaceutical activity from foods.
|
-
-
HY-L202
-
|
427 compounds
|
Flavor is an expression of smell and taste that is achieved through a variety of chemical processes triggered by molecules. Food flavor is an important attribute of food quality and in some cases determines consumers' food preferences. In addition to playing a key role in taste and smell, flavor molecules can also be involved in regulating metabolism and have an impact on health. In daily life, flavor molecules have absolute application value in food and spices. In scientific research, the study of flavor molecules is helpful to reveal the relationship between food intake and taste perception. Research on the combination behavior of flavor and food components can explore the retention, release and perception of flavor molecules. Most importantly, while exploring multi-sensory flavor perception, the food industry can fully mobilize the enthusiasm of researching new strategies for delicious and healthy food design.
Based on the FlavorDB database, collects and organizes 427 flavor molecules, which can be used in taste perception and other related studies.
|
Cat. No. |
Product Name |
Type |
-
- HY-W127334
-
|
Biochemical Assay Reagents
|
N-Palmitoyl phosphatidylethanolamine (Tripelargonin) is endogenous lipid anorectic hormone, significantly reduces food intake in a dose-dependent manner
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3651
-
CCK (26-33) (free acid)
|
Peptides
|
Metabolic Disease
|
Cholecystokinin (26-33) (CCK (26-33)) free acid is a cholecystokinin (CCK) fragment. Cholecystokinin (26-33) free acid can reduce food intake and gallbladder contraction .
|
-
- HY-P1215A
-
|
Melanocortin Receptor
|
Metabolic Disease
|
HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
|
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P1216A
-
|
Melanocortin Receptor
|
Neurological Disease
|
HS014 TFA is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors respectively. HS014 TFA increases food intake in free-feeding rats .
|
-
- HY-P1215
-
|
Melanocortin Receptor
|
Metabolic Disease
|
HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
|
-
- HY-113896
-
|
Peptides
|
Others
|
U-67827E is a cholecystokinin (CCK) agonist that decreases food intake over a prolonged period of time in baboons. U-67827E may affect the latency to food by inhibiting the movement of food in the stomach and magnifying a gastric distention signal .
|
-
- HY-P4689
-
|
Peptides
|
Metabolic Disease
|
Prolactin-Releasing Peptide (1-31) (rat) is a UHR-1/GRP10 receptor ligand. Prolactin-Releasing Peptide (1-31) (rat) reduces fasting-induced food intake, increases plasma levels of LH, FSH, and testosterone in rats .
|
-
- HY-P3652
-
|
Peptides
|
Metabolic Disease
|
Cholecystokinin-33 (swine) is a cholecystokinin (CCK) fragment. Cholecystokinin-33 (swine) can reduce food intake and gallbladder contraction .
|
-
- HY-P2046
-
|
Opioid Receptor
|
Neurological Disease
|
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .
|
-
- HY-P2210
-
|
GPR171
|
Metabolic Disease
|
BigLEN(mouse) is a potent and selective agonist of orphan G protein-coupled receptor 171 (GPR171), with a Kd of ∼0.5 nM. BigLEN(mouse) can be used to regulate responses associated with food intake and metabolism .
|
-
- HY-P2932
-
Cholecystokinin-33(human); CCK-33(human)
|
Peptides
|
Metabolic Disease
|
Cholecystokinin is a peptide hormone. Cholecystokinin, as a hunger suppressant, inhibits food intake and stimulates the digestion of fat and protein. Cholecystokinin can be used for the research of gastrointestinal system .
|
-
- HY-P3561
-
|
Melanocortin Receptor
|
Neurological Disease
|
Agouti-related Protein (AGRP) (83-132) Amide (human) is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
|
-
- HY-P3561A
-
|
Melanocortin Receptor
|
Neurological Disease
|
Agouti-related Protein (AGRP) (83-132) Amide (human) TFA is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
|
-
- HY-P3130
-
|
CRFR
|
Neurological Disease
Inflammation/Immunology
|
Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .
|
-
- HY-P1216
-
|
Melanocortin Receptor
|
Neurological Disease
|
HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats .
|
-
- HY-P1322
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
|
-
- HY-P1322A
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats .
|
-
- HY-P1306
-
|
GHSR
|
Cardiovascular Disease
Inflammation/Immunology
|
Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
|
-
- HY-P1306A
-
|
GHSR
|
Cardiovascular Disease
Inflammation/Immunology
|
Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
|
-
- HY-P1323
-
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
[Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake .
|
-
- HY-P1323A
-
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake .
|
-
- HY-P3463
-
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P0259
-
-
- HY-P2025
-
|
Peptides
|
Neurological Disease
|
JMV 236 is a cholecystokinin antagonist with appetite-suppressing activity. JMV 236 affects the regulation of food intake through the interaction of the intestinal endogenous peptide PrRP and the CCK1 receptor. The administration of JMV 236 activates PrRP neurons located in the NTS, thereby enhancing its appetite-suppressing effect. JMV 236 has significant effects on areas of the central nervous system associated with food intake, especially during states of starvation .
|
-
- HY-P1421A
-
|
Peptides
|
Metabolic Disease
|
Obestatin(human) TFA is an endogenous peptide derived from the same prepropeptide as ghrelin. Obestatin(human) suppresses food intake and reduce body weight-gain in rats.
|
-
- HY-107627
-
|
Melanocortin Receptor
|
Inflammation/Immunology
|
MCL0020 is a potent and selective melanocortin MC4 receptor antagonist, with an IC50 of 11.63 nM. MCL0020 dose-dependently and significantly attenuates restraint stress-induced anorexia without affecting food intake .
|
-
- HY-P4839
-
|
Peptides
|
Metabolic Disease
|
GLP-2 (1-34) (human) is a polypeptide released from the intestine within minutes after food intake. GLP-2 (1-34) (human) can be used for the research of bone remodeling processes .
|
-
- HY-P4815
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .
|
-
- HY-P10041
-
|
Peptides
|
Metabolic Disease
|
Obestatin(11-23)mouse, rat is a polypeptide involved in regulating energy balance and inhibiting eating. Obestatin(11-23)mouse, rat causes reduced food intake, body weight, and jejunal contractions in rodents .
|
-
- HY-P0198B
-
-
- HY-P2210A
-
|
Peptides
|
Neurological Disease
|
BigLEN(mouse) TFA is a GPR171 agonist. BigLEN(mouse) TFA is a proSAAS-derived neuropeptide. BigLEN(mouse) TFA regulates food intake in mice. BigLEN(mouse) inhibits the release of glutamate onto parvocellular neurons of the paraventricular nucleus in a process dependent upon activation of postsynaptic G proteins.
|
-
- HY-P1096
-
|
Cholecystokinin Receptor
|
Metabolic Disease
|
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
|
-
- HY-P2703
-
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system .
|
-
- HY-P1525
-
MCH (salmon)
|
MCHR1 (GPR24)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
|
-
- HY-P1296
-
Urocortin (Rattus norvegicus); Rat urocortin
|
CRFR
|
Neurological Disease
Endocrinology
|
Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively .
|
-
- HY-P1525A
-
MCH (salmon) (TFA)
|
MCHR1 (GPR24)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
|
-
- HY-P1317
-
|
Opioid Receptor
|
Neurological Disease
|
Nociceptin (1-13), amide is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
|
-
- HY-P1296A
-
Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA
|
CRFR
|
Neurological Disease
Endocrinology
|
Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively .
|
-
- HY-P1317A
-
|
Opioid Receptor
|
Neurological Disease
|
Nociceptin (1-13), amide TFA is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
|
-
- HY-P1349A
-
Rat orexin B TFA; Orexin B (mouse) (TFA)
|
Orexin Receptor (OX Receptor)
|
Neurological Disease
Endocrinology
|
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation .
|
-
- HY-P2242A
-
|
Melanocortin Receptor
|
Neurological Disease
Inflammation/Immunology
|
RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects .
|
-
- HY-P10380
-
|
Neuropeptide FF Receptor
|
Neurological Disease
|
palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
|
-
- HY-P5390
-
|
Peptides
|
Others
|
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)
|
-
- HY-P1324
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
|
-
- HY-P1324A
-
|
Neuropeptide Y Receptor
|
Neurological Disease
|
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
|
-
- HY-P5519
-
|
Peptides
|
Others
|
[Thr28, Nle31]-Cholecystokinin (25-33) is a biological active peptide. (Cholecystokinin (CCK) acts both as a hormone and a neurotransmitter and is found in the GI system and the central nervous system. It is a satiety peptide that inhibits food intake.This Cholecystokinin (CCK) analog retains all the bioactivities of CCK8, but was found to be remarkably more stable in acidic media and unaffected by air oxidation due to Met replacements (Thr 28 and Nle31 were substituted for Methionine). The predominant conformation contains a gamma-turn centered on Thr4, separated by Gly5 from a helical segment that comprises the C-terminal residues.)
|
-
- HY-P5390A
-
|
Peptides
|
Others
|
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99388
-
REGN-1033
|
Inhibitory Antibodies
|
Metabolic Disease
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W010042S
-
|
L-Glucose- 13C is the 13C labeled L-Glucose. L-Glucose (L-(-)-Glucose) is an enantiomer of D-glucose. L-Glucose can promote food intake[1][2].
|
-
-
- HY-W010042S1
-
|
L-Glucose- 13C-1 is the 13C labeled L-Glucose. L-Glucose (L-(-)-Glucose) is an enantiomer of D-glucose. L-Glucose can promote food intake[1][2].
|
-
-
- HY-W010042S2
-
|
L-Glucose- 13C-2 is the 13C labeled L-Glucose. L-Glucose (L-(-)-Glucose) is an enantiomer of D-glucose. L-Glucose can promote food intake[1][2].
|
-
-
- HY-W010042S3
-
|
L-Glucose- 13C6 (L-(-)-Glucose- 13C6) is C13-labeled L-Glucose. L-Glucose is an enantiomer of D-glucose. L-Glucose enhances food intake .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: